News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Our Chief Medical Officer, Tomasz, and Director of Clinical Operations, Karen, in Paris next week for COMy.
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Our Chief Medical Officer, Tomasz, and Director of Clinical Operations, Karen, in Paris next week for COMy.
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.
There is a continuing squeeze on hospitals and on oncology workforce capacity. There is a role for novel effective oral drugs taken at home, in the community.
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Our Chief Medical Officer, Tomasz, and Director of Clinical Operations, Karen, in Paris next week for COMy.
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.
There is a continuing squeeze on hospitals and on oncology workforce capacity. There is a role for novel effective oral drugs taken at home, in the community.
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Our Chief Medical Officer, Tomasz, and Director of Clinical Operations, Karen, in Paris next week for COMy.
Even with recent significant advances, the vast majority of people diagnosed with multiple myeloma ultimately still die of the disease.
Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.
Not all patients can access complex therapies. There will be an increasing need for treatments that can be taken at home, in the community.
There is a continuing squeeze on hospitals and on oncology workforce capacity. There is a role for novel effective oral drugs taken at home, in the community.
Latest press releases